Celldex Therapeutics, Inc. reported $158K of revenue over the trailing twelve months, −97% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $158K (to Q2 2026). Net income: −$301M, trailing twelve months to Q2 2026. Free cash flow: −$242M, trailing twelve months to Q2 2026. EPS: −$4.36, trailing twelve months to Q2 2026.

CLDXCelldex Therapeutics, Inc.

Healthcare

$29.89+21% 1Y

$29.89

$22.5852 weeks$44.88

CLDX as reported

Celldex Therapeutics, Inc. reported $158K of revenue over the trailing twelve months, −97% on the year before. 9 reported series are charted on this page, each one as filed.

$158K

Revenue, trailing twelve months · to Q2 2026 · −97% against the twelve months before

Net income: −$301M
Net income · +51% year on year · trailing twelve months to Q2 2026
Free cash flow: −$242M
Free cash flow · +28% year on year · trailing twelve months to Q2 2026
EPS: −$4.36
EPS · +45% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CLDX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$158K	−97%	Q2 2026
Net income	−$301M	+51%	Q2 2026
EPS	−$4.36	+45%	Q2 2026
Operating margin	−6044%	n/a	Q2 2025 · 4 quarters behind
Net margin	−5205%	n/a	Q2 2025 · 4 quarters behind
ROE	−48%	n/a	Q2 2026
ROA	−43%	n/a	Q2 2026
ROIC	−146%	n/a	Q1 2013 · 53 quarters behind
Free cash flow	−$242M	+28%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.